MD20150019A2 - Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile - Google Patents
Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubileInfo
- Publication number
- MD20150019A2 MD20150019A2 MDA20150019A MD20150019A MD20150019A2 MD 20150019 A2 MD20150019 A2 MD 20150019A2 MD A20150019 A MDA20150019 A MD A20150019A MD 20150019 A MD20150019 A MD 20150019A MD 20150019 A2 MD20150019 A2 MD 20150019A2
- Authority
- MD
- Moldova
- Prior art keywords
- 6alkyl
- compounds
- 3alkyl
- ome
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
Prezenta invenţie se referă la compuşi cu formula (I):(I)şi sărurile acceptabile farmaceutic ale acestora, unde A este o grupare heterociclil saturată cu 5...7 membri, conţinând un atom de azot şi opţional un atom de oxigen, unde un atom de carbon din gruparea heterociclil respectivă este substituit opţional cu una sau două grupări selectate dintre alchil-C1-3 şi oxo; R1 este un alchil-C1-4 substituit opţional cu o grupare metoxi; R2 este selectat dintre H, F, Cl, alchil-C1-3, -CN, -OMe şi -CF3; R3 este selectat dintre H şi -CH3; R4 este selectat dintre H, F, -CH3 şi -OMe; R5 este selectat dintre H, Cl, -CH3, -CH2CH3, -CF3, F, şi -OMe; R6 este legat de azotul din gruparea A şi este selectat dintre H, alchil-C1-6, -(CH2)n cicloalchil-C3-6, -C(O)-alchil-C1-6, -(CH2)n heterociclil, -(CH2)n aril -(CH2)n heteroaril, -SO2aril, SO2alchil-C1-6, unde alchil-C1-6, -(CH2)n heterociclil, -(CH2)n cicloalchil, -(CH2)n aril şi -(CH2)n heteroaril menţionate sunt substituite opţional cu 1…4 grupări selectate independent dintre alchil-C1-3, halogen, alcoxi-C1-3, -CF3, -OH, oxo, -(CH2)1-3O(CH2)2-3OH, şi -SO2CH3; R7 este selectat dintre H, -CH3, -CH2CH3, -CF3, F şi -CN.Invenţia se referă, de asemenea, la compoziţii farmaceutice, care cuprind aceşti compuşi, la metode de utilizare a acestora în tratamentul diverselor boli şi tulburări, la procedee de obţinere a acestor compuşi şi intermediari utili în procedeele date.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697899P | 2012-09-07 | 2012-09-07 | |
PCT/US2013/057826 WO2014039434A1 (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20150019A2 true MD20150019A2 (ro) | 2015-07-31 |
MD4425B1 MD4425B1 (ro) | 2016-06-30 |
MD4425C1 MD4425C1 (ro) | 2017-01-31 |
Family
ID=49170904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20150019A MD4425C1 (ro) | 2012-09-07 | 2013-09-03 | Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile |
Country Status (38)
Country | Link |
---|---|
US (2) | US8906904B2 (ro) |
EP (1) | EP2892891B1 (ro) |
JP (1) | JP5970134B2 (ro) |
KR (1) | KR101692707B1 (ro) |
CN (1) | CN104619695B (ro) |
AP (1) | AP2015008231A0 (ro) |
AR (1) | AR092869A1 (ro) |
AU (1) | AU2013312931B2 (ro) |
BR (1) | BR112015004529B1 (ro) |
CA (1) | CA2880494C (ro) |
CL (2) | CL2015000255A1 (ro) |
CY (1) | CY1122610T1 (ro) |
DK (1) | DK2892891T3 (ro) |
EA (1) | EA027244B1 (ro) |
EC (1) | ECSP15012804A (ro) |
ES (1) | ES2748798T3 (ro) |
GE (1) | GEP20176631B (ro) |
HK (1) | HK1210164A1 (ro) |
HR (1) | HRP20191755T1 (ro) |
HU (1) | HUE046996T2 (ro) |
IL (1) | IL236987A (ro) |
LT (1) | LT2892891T (ro) |
MA (1) | MA37891B1 (ro) |
MD (1) | MD4425C1 (ro) |
MX (1) | MX338887B (ro) |
NZ (1) | NZ703989A (ro) |
PE (1) | PE20151001A1 (ro) |
PH (1) | PH12015500457B1 (ro) |
PL (1) | PL2892891T3 (ro) |
PT (1) | PT2892891T (ro) |
RS (1) | RS59394B1 (ro) |
SG (2) | SG10201510668UA (ro) |
SI (1) | SI2892891T1 (ro) |
TN (1) | TN2015000054A1 (ro) |
TW (1) | TWI586661B (ro) |
UA (1) | UA115881C2 (ro) |
UY (1) | UY35012A (ro) |
WO (1) | WO2014039434A1 (ro) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20176631B (en) * | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TWI711615B (zh) | 2014-07-22 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為可溶性鳥苷酸環化酶活化劑的雜環羧酸 |
CA3008776A1 (en) | 2015-12-18 | 2017-06-22 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
SG11202011018PA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
MX2021000405A (es) * | 2018-07-12 | 2021-03-25 | Boehringer Ingelheim Int | Alcoxipirazoles como activadores de guanilato ciclasa soluble. |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
CN112079712B (zh) * | 2020-09-18 | 2022-12-13 | 江苏美迪克化学品有限公司 | 一种对乙烯基水杨酸的制备方法 |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
TW202402274A (zh) | 2022-03-21 | 2024-01-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療門脈高壓之可溶性鳥苷酸環化酶活化劑 |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
CA2428989A1 (en) | 2000-11-22 | 2002-05-30 | Visx Incorporated | Temperature actuated positioning device for non-linear optical elements |
GB0212785D0 (en) * | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
US20100016305A1 (en) | 2005-07-18 | 2010-01-21 | Bayer Healthcare Ag | novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
RU2009145935A (ru) | 2007-05-12 | 2011-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений |
EA201070339A1 (ru) * | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
CA2706241C (en) * | 2007-10-05 | 2015-12-22 | Sanofi-Aventis Deutschland Gmbh | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
WO2009071504A1 (en) | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
EP2264017A4 (en) | 2008-04-04 | 2011-07-27 | Takeda Pharmaceutical | Heterocyclic derivative and its use |
WO2010015652A2 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2010081647A2 (en) * | 2009-01-17 | 2010-07-22 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
BRPI1008793A2 (pt) | 2009-02-26 | 2016-03-08 | Merck Sharp & Dohme | composto, uso de um composto, e, composição farmacêutica |
WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
JP6143461B2 (ja) * | 2010-02-05 | 2017-06-07 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | sGC刺激剤又はsGC活性化剤単独及びPDE5阻害剤と組合せた嚢胞性線維症処置 |
NZ603799A (en) * | 2010-05-26 | 2014-10-31 | Bayer Ip Gmbh | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
EP2585055A1 (de) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2012122340A1 (en) | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
US8815857B2 (en) | 2011-08-12 | 2014-08-26 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
GEP20176631B (en) * | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2013
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en active Application Filing
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active IP Right Grant
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
-
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457B1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
- 2015-11-06 HK HK15110980.4A patent/HK1210164A1/xx unknown
-
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
-
2019
- 2019-09-26 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD20150019A2 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
PH12017500797A1 (en) | Substituted chromanes and methods of use | |
PH12017500111A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
JP2015537020A5 (ro) | ||
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
RU2014121205A (ru) | Производные азолов | |
AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
PH12015502692B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
MY165141A (en) | Pyrazolidin-3-one derivatives | |
MX348127B (es) | Derivados de quinazolinona como inhibidores del virus de la hepatitis c. | |
MX356759B (es) | Derivados de pirimidinona como agentes antimalaricos. | |
AR076942A1 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-carboxilico | |
NZ706283A (en) | Arylethynyl derivatives | |
AR095940A1 (es) | Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida | |
TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
TN2013000102A1 (en) | Pyrazine derivatives as enac blockers | |
MX2015006806A (es) | Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued |